Sai Parenterals hits 52 week high as its arm renews OTC medicines supply agreement with Australian pharmacy network
Sai Parenteral's is currently trading at Rs. 629.85, up by 18.45 points or 3.02% from its previous closing of Rs. 611.40 on the BSE.
The scrip opened at Rs. 685.25 and has touched a high and low of Rs. 705.00 and Rs. 627.00 respectively. So far 98434 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 5 has touched a 52 week high of Rs. 705.00 on 02-Jul-2026 and a 52 week low of Rs. 400.00 on 02-Apr-2026.
Last one week high and low of the scrip stood at Rs. 705.00 and Rs. 571.25 respectively. The current market cap of the company is Rs. 2,782.63 crore.
The promoters holding in the company stood at 51.16%, while Institutions and Non-Institutions held 18.59% and 30.26% respectively.
Sai Parenterals’ Australian subsidiary -- Noumed Pharmaceuticals has successfully renewed its long-term exclusive OTC Medicines Supply Agreement with one of Australia's leading, multi-billion-dollar pharmacy chains with an expanded product portfolio, a longer agreement tenure, and a significantly higher agreement value - reflecting a trusted customer relationship. The renewed agreement is valued at 202 million Australian dollar (around Rs 1300 crore) for the term - translating to about 27 million Australian dollar per annum - to be executed over an extended term of seven and half years - with a further 3-year extension option upon mutual consent.
The agreement is also structured for continuous growth: it targets the addition of 12 new products every year, steadily increasing the contract's value and scope every year over its life. Effective July 1, 2026, the renewal cements Noumed's position as a preferred, trusted strategic supply partner to Australia's largest pharmacy networks, and materially strengthens the company’s international business footprint.
